Key Highlights

  • Tactile Systems Technology (NASDAQ: TCMD) signed an exclusive U.S. Distribution deal for MyoSleeve targeting VA and DoD patients.
  • Tactile Systems Technology Inc (NASDAQ: TCMD) announced a strategic partnership on July 13, 2026 to expand the reach of its MyoSleeve wearable compression device.
  • The contract with ElastiMed, Inc. Grants TCMD exclusive rights to supply MyoSleeve to VA and DoD medical facilities.

Tactile Systems Technology Inc (NASDAQ: TCMD) announced a strategic partnership on July 13, 2026 to expand the reach of its MyoSleeve wearable compression device. The company will serve as the sole U.S.

Exclusive Distribution Agreement

The contract with ElastiMed, Inc. Grants TCMD exclusive rights to supply MyoSleeve to VA and DoD medical facilities. This arrangement aligns with TCMD’s goal of leveraging its existing sales platform and patient support services to accelerate adoption of the device in federal healthcare channels.

The cash outlay underscores the firm’s confidence in MyoSleeve’s market potential and its willingness to meet agreed‑upon purchase minimums and promotional benchmarks.

Product Overview and Clinical Indication

MyoSleeve is a discreet, battery‑powered sleeve that delivers dynamic compression using electroactive polymer bands.

Integration with Existing Therapies

The wearable may be used alongside traditional pneumatic compression systems or as a standalone solution for patients who find conventional therapy cumbersome. Clinicians will determine suitability on a case‑by‑case basis, expanding therapeutic options for early‑stage swelling cases.

Market Access and Commercialization Strategy

TCMD plans to tap its established billing expertise, logistics network, and veteran‑focused outreach programs to drive uptake of MyoSleeve within the VA and DoD. The company expects the distribution rights to enhance its revenue profile while supporting broader access to innovative compression technology.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.